|- Program aims to boost country capacity to combat diseases through vaccination
Seoul, KOREA - The International Vaccine Institute (IVI), a Seoul, Korea-based international organization, will kick-off ´the Eighth International Advanced Course on Vaccinology for the Asia Pacific Regions´ on May 5. The week-long training course for professionals is designed to help countries boost their capacity in the area of vaccine evaluation, introduction and policy.
The annual event will bring together over 70 participants from more than 20 countries, including Cuba, Columbia, Brazil, the United States and Tanzania, as well as Asian nations such as Korea and China. The participants include scientists, public health officials and policymakers involved in vaccine development and vaccination policies, both from the private and public sectors.
|The International Vaccine Institute (IVI) kicked off ‘the Eighth International Advanced Course on Vaccinology for the Asia Pacific Regions´ at its headquarters in Seoul on May 5, 2008. The week-long training course for professionals, which is designed to help countries boost their capacity in the area of vaccine evaluation, introduction and policy, brought together more than 70 participants from over 20 countries worldwide, as well as over 20 leading experts in vaccinology who served as faculty.
The course aims to help countries, especially in the developing world, better cope with the threat of infectious diseases, including emerging diseases such as avian influenza, by expanding their understanding of key issues related to vaccine development, production, evaluation and introduction. Fifteen fellowships are granted each year to participants from developing countries to support their participation.
More than 20 experts from the IVI, universities, research institutions, industry, non-profit organizations, and international agencies (including the World Health Organization and the GAVI Alliance) will serve as faculty for the course. Prof. Ian Gust, a leading virologist and vaccine expert from the University of Melbourne, will make a keynote closing speech on May 10 entitled, "The Future of vaccines and vaccination with special emphasis on avian flu and other pandemics." He will present an overview of the history of vaccines and recent trends in vaccinology, and focus on the need to address the gap between developed and developing countries in immunization coverage and the availability and use of new-generation vaccines.
The participants will discuss the entire vaccine continuum, from discovery in the laboratory to vaccine evaluation, licensure and regulatory issues, production, introduction strategies and financing mechanisms. The course covers a range of disciplines, including the basics of epidemiology and immunology, the latest in vaccine technology and delivery systems, vaccine economics and financing, and ethical issues related to field testing and delivery of vaccines. It also covers a range of infectious diseases and vaccines, including those against enteric diseases (rotavirus, cholera, and typhoid fever), respiratory diseases such as influenza and Haemophilus influenzae type b (Hib), Flaviviruses such as Japanese encephalitis and dengue fever, malaria and human papilloma virus (HPV).
The course comprises lectures, case studies, and roundtable discussions designed to encourage interaction between participants and faculty. Topics for discussion include "technology transfer," "the changing regulatory environment," and "rotavirus vaccine introduction."
The event is jointly hosted by the IVI and the London School of Hygiene and Tropical Medicine, and sponsored by the Ministry of Education, Science and Technology of Korea, GlaxoSmithKline Biologicals, the Bill & Melinda Gates Foundation, and the Korea Exchange Bank Foundation.
The International Vaccine Institute (IVI) is the world´s only international organization devoted exclusively to developing and introducing new and improved vaccines to protect the world´s poorest people, especially children in developing countries. Established as an initiative of the United Nations Development Program in 1997, the IVI operates under a treaty signed by 40 countries and the World Health Organization. The Institute conducts research in more than 20 countries of Asia, Africa and Latin America on vaccines against diarrheal infections, bacterial meningitis and pneumonia, as well as Japanese encephalitis and dengue fever, and develops new and improved vaccines at its headquarters in Seoul. For more information, please visit www.ivi.int